Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Buy
56
NVZMY Quote, Financials, Valuation and Earnings
Last price:
$64.91
Seasonality move
:
6.96%
Day range:
$62.67 - $65.00
52-week range:
$52.96 - $72.50
Dividend yield:
1.88%
P/E ratio:
28.54x
P/S ratio:
4.35x
P/B ratio:
2.54x
Volume:
6.3K
Avg. volume:
48.2K
1-year change:
13.96%
Market cap:
$29.5B
Revenue:
$4.1B
EPS (TTM):
$2.23
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Novonesis (Novozymes) B has -- downside to fair value with a price target of -- per share.
NVZMY vs. S&P 500
-
Over the past 5 trading days, Novonesis (Novozymes) B has overperformed the S&P 500 by 1.07% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Novonesis (Novozymes) B does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Novonesis (Novozymes) B has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Novonesis (Novozymes) B reported revenues of $2.1B.
Earnings Growth
-
Novonesis (Novozymes) B has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Novonesis (Novozymes) B reported earnings per share of $0.56.
Enterprise value:
31.1B
EV / Invested capital:
--
Price / LTM sales:
4.35x
EV / EBIT:
28.32x
EV / Revenue:
6.60x
PEG ratio (5yr expected):
1.27x
EV / Free cash flow:
102.04x
Price / Operating cash flow:
63.14x
Enterprise value / EBITDA:
28.32x
Gross Profit (TTM):
$2.5B
Return On Assets:
11.12%
Net Income Margin (TTM):
15.27%
Return On Equity:
12.12%
Return On Invested Capital:
15.78%
Operating Margin:
21.76%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $2.5B | $3.2B | $4.7B | $1.3B | $2.1B | |
| Gross Profit | $1.4B | $1.8B | $2.5B | $705.3M | $1.1B | |
| Operating Income | $626.5M | $831.7M | $1.1B | $338.1M | $464.2M | |
| EBITDA | $665.3M | $806.1M | $1.1B | $338.1M | $464.2M | |
| Diluted EPS | $1.86 | $2.07 | $2.23 | $0.85 | $0.56 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.1B | $1.2B | $1.3B | $1.4B | $2B | |
| Total Assets | $3.4B | $3.8B | $4B | $4.2B | $15.8B | |
| Current Liabilities | $687.8M | $863.6M | $1B | $1.1B | $1.1B | |
| Total Liabilities | $1.5B | $1.9B | $2B | $2.1B | $4.2B | |
| Total Equity | $1.9B | $1.9B | $2B | $2.1B | $11.6B | |
| Total Debt | -- | $308.9M | $926.5M | $1.1B | $1.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2022-12-31 | 2023-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $646.2M | $567M | $603.1M | $103.4M | $161.7M | |
| Cash From Investing | -$437M | -$378.2M | -$309.8M | -$137.9M | -$87M | |
| Cash From Financing | -$252.3M | -$176.9M | -$274.4M | -$4.5M | -$80.1M | |
| Free Cash Flow | $448.9M | $158M | $304.5M | -$36M | $74.7M | |
NVZMY
Sector
Market Cap
$29.5B
$18.2M
Price % of 52-Week High
87.63%
62.16%
Dividend Yield
1.88%
0%
Shareholder Yield
--
1.27%
1-Year Price Total Return
13.96%
-15.57%
Beta (5-Year)
0.910
0.918
Dividend yield:
1.88%
Annualized payout:
$0.58
Payout ratio:
24.37%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$62.93
200-day SMA
Buy
Level
$61.50
Bollinger Bands (100)
Buy
Level
56.1 - 60.6
Chaikin Money Flow
Buy
Level
6.1M
20-day SMA
Buy
Level
$60.94
Relative Strength Index (RSI14)
Buy
Level
60.68
ADX Line
Buy
Level
8.78
Williams %R
Sell
Level
-14.4118
50-day SMA
Buy
Level
$59.69
MACD (12, 26)
Buy
Level
1.22
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
5.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.2564)
Buy
CA Score
(Annual)
Level (0.8644)
Sell
Beneish M-Score
(Annual)
Level (-1.4516)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-2.0161)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
Stock Forecast FAQ
In the current month, NVZMY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NVZMY average analyst price target in the past 3 months is --.
-
Where Will Novonesis (Novozymes) B Stock Be In 1 Year?
According to analysts, the consensus estimate is that Novonesis (Novozymes) B share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Novonesis (Novozymes) B?
Analysts are divided on their view about Novonesis (Novozymes) B share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Novonesis (Novozymes) B is a Sell and believe this share price will rise from its current level to --.
-
What Is Novonesis (Novozymes) B's Price Target?
The price target for Novonesis (Novozymes) B over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NVZMY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Novonesis (Novozymes) B is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NVZMY?
You can purchase shares of Novonesis (Novozymes) B via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Novonesis (Novozymes) B shares.
-
What Is The Novonesis (Novozymes) B Share Price Today?
Novonesis (Novozymes) B was last trading at $64.91 per share. This represents the most recent stock quote for Novonesis (Novozymes) B. Yesterday, Novonesis (Novozymes) B closed at $63.53 per share.
-
How To Buy Novonesis (Novozymes) B Stock Online?
In order to purchase Novonesis (Novozymes) B stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is down 5.48% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 1.82% over the past day.
Sell
16
NSP alert for Apr 30
Insperity [NSP] is down 3.3% over the past day.
